FindTrial
Sign In

A Study to Evaluate the Efficacy and Safety of AD-209

A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05631990
Enrollment
221
Registered
2022-11-30
Start date
2023-04-05
Completion date
2023-11-27
Last updated
2024-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Essential

Brief summary

The purpose of this study is to evaluate the efficacy and safety of AD-209

Detailed description

Condition or disease : hypertension Intervention/treatment Drug : AD-209 Drug : AD-209-1A Drug : AD-209-1B Drug : AD-209-1C Drug : AD-209 Placebo Drug : AD-209-1 Placebo Phase : Phase 2

Interventions

DRUGAD-209

PO, Once daily(QD), 8weeks

DRUGAD-209-1A

PO, Once daily(QD), 8weeks

DRUGAD-209-1B

PO, Once daily(QD), 8weeks

DRUGAD-209-1C

PO, Once daily(QD), 8weeks

DRUGAD-209 placebo

PO, Once daily(QD), 8weeks

DRUGAD-209-1 placebo

PO, Once daily(QD), 8weeks

Sponsors

Addpharma Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Other inclusions applied

Exclusion criteria

* orthostatic hypotension with symptom * Other exclusions applied

Design outcomes

Primary

MeasureTime frameDescription
Change rate of MSSBPBaseline, Week 8Change from baseline in mean sitting systolic blood pressure

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026